| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
β-Zearalenol targets the estrogen receptor α (ERα), acting as an agonist. By binding to and activating ERα, it mimics the effects of estrogen, leading to estrogenic responses such as increased cell proliferation in ERα-positive cells. It has an EC₅₀ of 8.49 nM for increasing the proliferation of MCF-7 cells that endogenously express ERα. Its potent estrogenic activity makes it a significant mycotoxin of concern for food safety and animal health. It may also interact with other estrogen receptors and signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, β-Zearalenol is a potent agonist of ERα, with an EC₅₀ of 8.49 nM for increasing the proliferation of MCF-7 cells that endogenously express ERα. Its activity is typically assessed in cell-based proliferation assays using ERα-positive breast cancer cell lines such as MCF-7. The compound's estrogenic activity is confirmed by its ability to activate estrogen-responsive reporter genes. Its potency is compared to that of estradiol and other estrogenic compounds.
|
| ln Vivo |
In vivo, β-Zearalenol is a mycotoxin that can cause estrogenic effects in animals. Its potent estrogenic activity can lead to reproductive disorders in livestock, including infertility, reduced litter size, and other reproductive abnormalities. The compound is a concern for food safety due to its presence in contaminated cereals and animal feed. It is not used as a therapeutic agent.
|
| Enzyme Assay |
In vitro non-cell enzyme/receptor binding assays for β-Zearalenol involve measuring its binding affinity to ERα. Radioligand binding studies using purified ERα and a labeled ligand (e.g., [³H]estradiol) are used to determine its affinity. Its ability to activate ERα can be assessed in cell-free transcription assays. These assays provide quantitative data on the compound's interactions with its molecular target.
|
| Cell Assay |
In vitro cell-based assays for β-Zearalenol use ERα-positive breast cancer cell lines such as MCF-7. Cells are treated with varying concentrations of the compound, and cell proliferation is assessed using MTT or similar assays to determine the EC₅₀ of 8.49 nM. The compound's ability to activate estrogen-responsive genes is measured by qPCR or reporter gene assays. These studies help to characterize the compound's estrogenic activity and potency.
|
| Animal Protocol |
In vivo animal studies for β-Zearalenol are typically toxicological studies to assess its effects on reproductive function. Animals are exposed to the compound through contaminated feed, and parameters such as reproductive performance, hormone levels, and organ weights are assessed. Its estrogenic effects are evaluated by measuring uterine weight and other estrogen-responsive endpoints.
|
| ADME/Pharmacokinetics |
β-Zearalenol has a molecular weight of 320.38 g/mol and a molecular formula of C₁₈H₂₄O₅. It is a mycotoxin belonging to the zearalenone family. The compound should be stored under appropriate conditions, typically at -20°C, protected from light and moisture. Its stability in solution is good under proper storage conditions.
|
| Toxicity/Toxicokinetics |
β-Zearalenol is a mycotoxin with potent estrogenic activity. It can cause reproductive disorders in animals and is a concern for food safety. The compound is not intended for human or veterinary use. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
|
| Additional Infomation |
β-Zearabenol is a macrolide antibiotic.
β-Zearalenol is a mycotoxin belonging to the zearalenone family, produced by Fusarium species. It is an agonist of ERα and increases the proliferation of MCF-7 cells with an EC₅₀ of 8.49 nM. Not a therapeutic agent; a mycotoxin of concern for food safety. |
| Molecular Formula |
C18H24O5
|
|---|---|
| Molecular Weight |
320.38016
|
| Exact Mass |
320.162
|
| CAS # |
71030-11-0
|
| PubChem CID |
6437352
|
| Appearance |
White to off-white solid powder
|
| Density |
1.174g/cm3
|
| Boiling Point |
599ºC at 760 mmHg
|
| Melting Point |
137-139ºC
|
| Flash Point |
217.9ºC
|
| Index of Refraction |
1.548
|
| LogP |
3.371
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
23
|
| Complexity |
408
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C[C@H]1CCC[C@H](CCC/C=C/C2=C(C(=CC(=C2)O)O)C(=O)O1)O
|
| InChi Key |
FPQFYIAXQDXNOR-PMRAARRBSA-N
|
| InChi Code |
InChI=1S/C18H24O5/c1-12-6-5-9-14(19)8-4-2-3-7-13-10-15(20)11-16(21)17(13)18(22)23-12/h3,7,10-12,14,19-21H,2,4-6,8-9H2,1H3/b7-3+/t12-,14-/m0/s1
|
| Chemical Name |
(4S,8S,12E)-8,16,18-trihydroxy-4-methyl-3-oxabicyclo[12.4.0]octadeca-1(14),12,15,17-tetraen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~312.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1213 mL | 15.6065 mL | 31.2129 mL | |
| 5 mM | 0.6243 mL | 3.1213 mL | 6.2426 mL | |
| 10 mM | 0.3121 mL | 1.5606 mL | 3.1213 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
